Key result
Angiotensin II drives ERK activation via transient nuclear G protein and sustained cytosolic beta-arrestin pathways.
Angiotensin II activates ERK through two spatially and temporally distinct pathways (G protein-dependent and beta-arrestin-dependent), suggesting potential for pathway-selective therapeutic ligands.
Answers are grounded in this paper and cite their sources.
Does not support changes to renin-angiotensin therapies; leaves open biased ligands selectively targeting compartmentalized ERK pathways.
Beta-arrestin, originally identified as a protein that inhibits heterotrimeric guanine nucleotide-binding protein (G protein) coupling to cognate seven-transmembrane receptors [(7TMRs), also known as G protein-coupled receptors (GPCRs)], is currently being appreciated as a positive signaling mediator for various cell surface receptors. Activation of mitogen-activated protein kinases (MAPKs), especially extracellular signal regulated kinases 1 and 2 (ERK1/2), is a hallmark of intracellular signaling resulting from stimulation of various growth factor receptors, as well as 7TMRs. The resulting ERK activity can occur through multiple parallel or converging mechanisms. Using human embryonic kidney 293 (HEK-293) cells as a model system and utilizing RNA interference technology, two distinct pathways of angiotensin II-mediated ERK activation have been uncovered: (i) a G protein-dependent pathway that produces a transient activation of nuclear ERK and (ii) a beta-arrestin-dependent pathway that leads to sustained activation of ERK that is localized to the cytosol and endosomes. The spatial and temporal segregation of ERK activated by G protein and beta-arrestin pathways suggests that the physiological consequences may be different, and thus ligands that selectively stimulate or inhibit one of these pathways may be therapeutically valuable.
No takes yet. Share an insight, caveat, or question.
Shenoy et al. (2005) studied this question. Angiotensin II was evaluated on ERK activation pathways. Angiotensin II stimulates ERK activation through two distinct pathways in HEK-293 cells: a transient G protein-dependent nuclear pathway and a sustained beta-arrestin-dependent cytosolic pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: